Brief: Clarity Pharmaceuticals Announce Exclusive License From Memorial Sloan Kettering Cancer Center
07/08/2023 02:38
Aug 7 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* ANNOUNCE AN EXCLUSIVE LICENSE FROM MEMORIAL SLOAN
KETTERING
CANCER CENTER
* LICENSE FOR INTELLECTUAL PROPERTY THAT COVER TECHNOLOGY TO
ENABLE ANTIBODY "PRE-TARGETING" FOR DIAGNOSIS OF CANCER
Source text for Eikon: ID:nASX2mfV9Y
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial